Redefining the target: Chemotherapeutics as antiangiogenics

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1195-1206

  Miller, K D ^a   Sweeney, C J ^a   Sledge G W , Jr ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EDELFOSINE; EPIRUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; TEGAFUR; TOPOTECAN; UFT; UNINDEXED DRUG; URACIL; VINBLASTINE; VINCRISTINE;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; DRUG EFFECT; METASTASIS; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

EID: 0035865363     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1195     Document Type: Review

References (139)

1. Tumor angiogenesis: Therapeutic implications
2. What is the evidence that tumors are angiogenesis dependent?
3. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
4. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma
5. Microvessel density is a prognostic indicator for patients with astroglial brain tumors
6. Microvessel density in brain tumors
7. Angiogenesis in breast cancer. Role in biology, tumor progression, and prognosis
8. Tumor angiogenesis and metastasis - Correlation in invasive breast cancer
9. Tumor vascularity - A novel prognostic factor in advanced cervical carcinoma
10. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia
11. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
12. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
13. Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer
14. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease
15. Correlation of angiogenesis with disease activity in patients with acute myeloid leukemia
16. All-trans retinoic acid inhibits vascular endothelial growth factor mediated angiogenesis in acute promyelocytic leukemia
17. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
18. Angiogenesis-regulating cytokines: Activities and interactions
19. Mechanisms of angiogenesis
20. Signaling vascular morphogenesis and maintenance
21. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
22. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
23. Quantification of cells cultured on 96-well plates
24. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer
25. Mechanisms of neovascularization: Vascular sprouting can occur without proliferation of endothelial cells
26. Endothelial cell differentiation into capillary-like structures in response to tumour cell conditioned medium: A modified chemotaxos chamber assay
27. Angiogenesis in vitro
28. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices
29. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms
30. Overcoming resistance to the anti-angiogenic properties of docetaxel induced by endothelial cell stimulation
31. Tumor necrosis factor type a, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo
32. Quantitative angiogenesis assays: Progress and problems
33. The preclinical evaluation of angiogenesis inhibitors
34. Tumor-induced angiogenesis: Lack of inhibition by irradiation
35. The chick embryo chorioallantoic membrane as a bioassay for angiogenesis factors: Reactions induced by carrier materials
36. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane
37. Tumor growth and neovascularization: An experimental model using the rabbit cornea
38. A corneal micropocket assay for angiogenesis in the rat eye
39. Angiogenesis in the mouse cornea
40. Ocular neovascularization with retinal vascular occlusion, I. Association with experimental retinal vein occlusion
41. Phthalocyanine photodynamic therapy of experimental iris neovascularization
42. The rat Subcutaneous Air Sac model: A quantitative assay of antiangiogenesis in induced vessels
43. The rat subcutaneous air sac model: A new and simple method for in vivo screening of antiangiogenesis
44. A new method for the microscopic study of living growing tissues by the introduction of a transparent chamber in the rabbit's ear
45. An adaptation of the transparent chamber technique to the mouse
46. Quantitation and physiological characterization of angiogenic vessels in mice: Effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment
47. Tumor angiogenesis: Transfilter diffusion studies in the hamster by the transparent chamber technique
48. Primary tumor size-dependent inhibition of angiogenesis at a secondary site: An intravital microscopic study in mice
49. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor beta1
50. Characterization and applications of the disc angiogenesis system
51. Application of the disc angiogenesis system to tumor-induced neovascularization
52. Basement membrane complexes with biological activity
53. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing
54. Factors influencing blood supply in wound granuloma quantitated by a new in vivo technique
55. An in vivo quantitative angiogenesis model using tumor cells entrapped in alginate
56. Tumor angiogenesis: A quantitative method for histologic grading
57. Neovascularization in human cutaneous melanoma: A quantitative morphological and Doppler ultrasound study
58. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis
59. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
60. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin
61. Genetic heterogeneity of angiogenesis in mice
62. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model
63. Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models
64. Endothelial injury caused by antineoplastic agents
65. Antiangiogenesis is produced by nontoxic doses of vinblastine
66. The microtubule-affecting drug paclitaxel has antiangiogenic activity
67. Antiangiogenic potential of camptothecin and topotecan
68. Inhibition of angiogenesis by anthracyclines and titanocene dichloride
69. Chemotherapy agents as antiangiogenic therapy
70. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process
71. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro
72. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
73. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo
74. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications
75. Cell kinetic studies of endothelial cells in the adenocarcinoma EO 771 and the effect of cyclophosphamide
76. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis
77. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development
78. Ocular angiogenesis: A new in vivo experimental model
79. Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice
80. Paclitaxel: A chemotherapeutic agent for prevention of restenosis? Experimental studies in vitro and in vivo
81. Taxol involution of collagen-induced arthritis: Ultrastructural correlation with the inhibition of synovitis and neovascularization
82. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis
83. A cancer therapy resistant to resistance
84. Genes expressed in human tumor endothelium
85. Mrpl multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells
86. Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers
87. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors
88. Drug resistance and P-glycoprotein expression in endothelial cells of newly formed capillaries induced by tumors
89. Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory, mechanisms
90. Expression of vascular endothelial growth factor and its receptor. KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
91. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling
92. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
93. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
94. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
95. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms
96. Carboplatin differentially induces the VEGF stress response in endothelial cells: Potentiation of anti-tumor effects by combination treatment with antibody to VEGF
97. Genetic instability and darwinian selection in tumours
98. Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP
99. Cyclooxygenase-2 mediates hypoxia induced vascular endothelial growth factor expression
100. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma
101. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
102. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
103. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
104. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer
105. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
106. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with serum vascular endothelial growth factor
107. High-time for chemotherapy or high time for low dose
108. Angiostatic activity of anticancer agents in the chick chorioallantoic membrane assay
109. Effects of anticancerous agents on the microvascular system of experimental malignant tumors
110. The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo
111. Suramin prevents neovascularization and tumour growth through blocking of basic fibroblast growth factor activity
112. Effects of radiotherapy and estramustine on the microvasculature in malignant glioma
113. Tumor blood flow and the cytotoxic effects of estramustine and its constituents in a rat glioma model
114. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture
115. Inhibitory effects of anti-angiogenic agents on neovascularization and growth of the chorioallantoic membrane. The possibility of a new CAM assay for angiogenesis inhibition
116. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice
117. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low dose methotrexate
118. Azathioprine and 6-mercaptopurine alter the nucleotide balance in endothelial cells
119. Anti-metastatic and anti-angiogenic activity of UFT in a lung spontaneous metastasis model in mice
120. Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma 26
121. Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene
122. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells
123. Antiangiogenic effects of camptothecin analogues 9-Amino-20(S)-camptothecin. Topotecan, and CPT-11 studied in the mouse cornea model
124. Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)
125. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol
126. A mechanism of cisplatin action: Antineoplastic effect through inhibition of neovascularization
127. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate
128. Effect of Octreotide on experimental corneal neovascularization
129. Suramin inhibits C6 glioma induced angiogenesis in vitro
130. Antiproliferative and angiostatic activity of suramin analogues
131. Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in BALB/c mice
132. Effects of Suramin on anastomotic colon tumors in a rat model
133. Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro
134. Effect of cisplatin and BCNU on MMP-2 levels in human glioblastoma cell lines in vitro
135. Selective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin
136. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin
137. Extracellular matrix inhibits apoptosis and enhances endothelial cell differentiation by a NfkappaB-dependent mechanism
138. Modulation of urokinase-type plasminogen activator and metalloproteinase activities in cultured mouse mammary-carcinoma cells: Enhancement by paclitaxel and inhibition by nocodazole
139. Ovarian cancer cell invasion is inhibited by paclitaxel